For the Inventor, By the Inventor

Enter assignee name

Hamilton, NJ, United States of America

Medical Diagnostic Laboratories, LLC

Calculating rank

USPTO Granted Patents = 80

% Expired Patents = 77.5

EPO Patents = 1

Trademarks = 40

Forward Citations = 129

Loading Chart...

Loading Chart...

61 inventors (with patents filed for the assignee):

Martin E Adelson (35 out of 37 patents)

Eli Mordechai (34 out of 37 patents)

Grant E Gallagher (19 out of 25 patents)

4. Jason Trama (13 out of 14 patents)

5. John G Hoey (13 out of 13 patents)

6. Raymond Yu (11 out of 11 patents)

7. Scott E Gygax (9 out of 10 patents)

8. Jonathan Brazaitis (9 out of 9 patents)

9. Lisa P Huang (9 out of 9 patents)

10. Joyce Eskdale (8 out of 10 patents)

11. Denise P Dimitrov (8 out of 8 patents)

12. Rachael Siegel (6 out of 6 patents)

13. Antara Datta (5 out of 5 patents)

14. Melanie Feola (5 out of 6 patents)

15. Lyndi Rice (4 out of 4 patents)

Core Competencies:

Biomarkers

Cell-Based Assays

Cancer Detection

IL-23 Receptor

mTOR Activity

Bladder Cancer

Microflora Profiling

IFN-Lambda

Tumor Susceptibility

Gene Silencing

Nucleic Acids

Exon Skipping

80 patents: Sort by Forward Citations

1. 11702666 - Cell-based assay for determining activity in the retinoblastoma pathway (2023-07-18),

2. 11692195 - Cell-based assay for determining activity in the retinoblastoma pathway (2023-07-04),

3. 11485763 - Cell-based assay for determining mTOR activity (2022-11-01),

4. 11319601 - Cell based assay (2022-05-03),

5. RE49026 - Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof (2022-04-11),

6. 11180766 - Cell-based assay for determining activity in the retinoblastoma pathway (2021-11-23),

7. 10845365 - ELISA detection of urine DEK to predict and diagnose bladder cancer in humans (2020-11-24),

8. 10416172 - Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling (2019-09-17),

9. 10351609 - Cell-based assay for determining mTOR activity (2019-07-16),

10. 10221462 - [object Object] (2019-03-05),

11. 10208357 - Cell based assay (2019-02-19),

12. 10167472 - PME-1 as a biomarker to predict and diagnose an increased risk of endometrial cancer and gene silencing of PME-1 to inhibit epithelial to mesenchymal transition (2019-01-01),

13. 10144974 - Methods and reagents that specifically detect, distinguish and quantify IFN-LAMBDA2 mRNA from IFN-LAMBDA3 mRNA in humans (2018-12-04),

14. 10041130 - [object Object] (2018-08-07),

15. 9970060 - Quantitation and profiling of vaginal microflora (2018-05-15),

Company Overview

Medical Diagnostic Laboratories, LLC, based in Hamilton, NJ, specializes in advanced medical diagnostics with a focus on innovative technologies for cancer detection and biomarker analysis. The company develops and manufactures cell-based assays that leverage insights into mTOR activity and the IL-23 receptor, contributing to the understanding of various cancers, including bladder cancer. Additionally, their expertise extends to microflora profiling and the role of IFN-Lambda in health, enhancing diagnostic capabilities in personalized medicine.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

80 Patents

#1 in Hamilton, NJ

#204 in New Jersey

#4,633 in US

#9,452 in the World

Hamilton, NJ, United States of America

Medical Diagnostic Laboratories, LLC

Forward Citations = 129

61 inventors:

Martin E Adelson (35 out of 37 patents)

Eli Mordechai (34 out of 37 patents)

Grant E Gallagher (19 out of 25 patents)

4. Jason Trama (13 out of 14 patents)

5. John G Hoey (13 out of 13 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Medical Diagnostic Laboratories, LLC. Retrieved from https://idiyas.com/company/medical-diagnostic-laboratories

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…